Share 'PPMD Working with FDA to Plan Landmark Pediatric Advisory Committee Meeting to Improve Clinical Trial Experience'
Later this spring – likely on or about May 18 – FDA’s Pediatric Advisory Committee will convene to consider the issue of allowing in-dwelling ports in Sarepta’s Essence trial.
Once again, our community is at a pivotal moment in our history where we can affect change and improve the clinical trial experience for our children.
Time and again in our Duchenne community, we see brav…
You can share this blog post in two ways…
Share this link:
Send it with your computer's email program: Email this